PAL Investors Have Opportunity to Join Proficient Auto Logistics, Inc. Fraud Investigation with the Schall Law Firm
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Proficient Auto announced its Q1 financial results on May 7, 2025. The Company suffered a decline in year-over-year total operating revenue as well as reporting a net operating loss. Based on this news, shares of Proficient Auto fell by more than 4.9% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Alliance Resource Partners, L.P. Announces Second Quarter 2025 Earnings Conference Call
TULSA, Okla., July 14, 2025--(BUSINESS WIRE)--Alliance Resource Partners, L.P. (NASDAQ: ARLP) will report its second quarter 2025 financial results before the market opens on Monday, July 28, 2025. Alliance management will discuss these results during a conference call beginning at 10:00 a.m. Eastern that same day. To participate in the conference call, dial U.S. Toll Free (877) 407-0784 and request to be connected to the Alliance Resource Partners, L.P. earnings conference call. International callers should dial (201) 689-8560 and request to be connected to the same call. Investors may also listen to the call via the "Investors" section of ARLP's website at An audio replay of the conference call will be available for approximately one week. To access the audio replay, dial U.S. Toll Free (844) 512-2921; International Toll (412) 317-6671 and request to be connected to replay using access code 13754521. About Alliance Resource Partners, L.P. ARLP is a diversified energy company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy and related infrastructure. News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission ("SEC"), are available at For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@ View source version on Contacts Investor Relations Contact Cary P. MarshallSenior Vice President and Chief Financial Officer(918) 295-7673investorrelations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042
MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity's patent exclusivity in the U.S. into 2042. 'This dosing regimen patent reflects our commitment to enhancing our intellectual property portfolio,' said Brian Sullivan, CEO and Co-Founder of Celcuity. 'With patent exclusivity for gedatolisib now extended into 2042, we expect to have a long runway to optimize development of gedatolisib.' The United States Patent and Trademark Office previously issued five U.S. patents directed to gedatolisib's composition of matter, four U.S. patents directed to various formulations comprising gedatolisib, and three U.S. patents directed to methods of using gedatolisib. The worldwide gedatolisib-related patent portfolio now comprises 13 granted gedatolisib-related patents in the U.S. and 290 patents granted in foreign jurisdictions. Celcuity expects to announce topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial in the third quarter of 2025 and to report topline data for the PIK3CA mutant cohort in the fourth quarter of 2025. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR ('PAM') pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to patent scope and length of protection and the anticipated timing of topline data from the VIKTORIA-1 clinical trial. Words such as, but not limited to, 'look forward to,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'intend,' "confidence," "encouraged," 'potential,' 'plan,' 'targets,' 'likely,' 'may,' 'will,' 'would,' 'should' and 'could,' and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that generics or others could challenge the validity of the gedatolisib patents, Celcuity may not be able to enforce the patents, there could be patent-related litigation or the progress of the VIKTORIA-1 clinical trial may be delayed. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. View source version of release on Contacts: Celcuity Sullivan, bsullivan@ Hahne, vhahne@ 392-0123 ICR HealthcarePatti Bank, 513-1284Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
an hour ago
- Wall Street Journal
Want to Know Where the Economy Is Headed? Look at These Banks
It's been a tale of two markets in U.S. banking of late: Some of the best of times for megabanks, and not-so-great times for smaller lenders. In the second quarter, the KBW Nasdaq Bank Index, which tracks the country's largest banks, was up 14%, beating the S&P 500 by about 3 percentage points. That was powered by some megabanks. Shares of Goldman Sachs GS -0.59%decrease; red down pointing triangle, for example, were up almost 30%.
